AllSci News
Brii Bio's HBV combo strategy validated, but Vir dispute clouds Phase III path
Brii Biosciences Limited reported end-of-treatment data from two Phase IIb studies that clarify the optimal combination strategy for BRII-179 in chronic HBV...
FDA halts Ascelia’s Orviglance approval, demands additional clinical data
Sweden-based Ascelia Pharma AB (STO: ACE) disclosed on July 3, 2026 that the US FDA issued a Complete Response Letter (CRL) for…
Otsuka's Astex strikes USD 515m breast cancer deal with Genentech on FBDD platform
Genentech has entered an exclusive worldwide research collaboration and license agreement with UK-based Astex Pharmaceuticals, paying USD 25 million upfront...
Junshi Bio hands Fosun Wanbang China commercial rights to roconkibart
China-based biopharma Shanghai Junshi Biosciences Co., Ltd. (HKEX: 01877) has granted Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. exclusive development, registration, and…
Scribe Therapeutics files for Nasdaq IPO with clinical-stage cardiovascular CRISPR pipeline
Scribe Therapeutics Inc. (Nasdaq: SCTX), a clinical-stage gene editing company co-founded by Nobel Laureate Dr. Jennifer Doudna and backed by more than USD...
Arcturus secures Thermo Fisher to manufacture inhaled mRNA therapy for Phase III cystic fibrosis trial
San Diego-based Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) and Thermo Fisher Scientific announced a strategic manufacturing and clinical research collaboration to support…
Sanyou Bio pairs with Baiyunshan for AI-powered radiopharmaceutical pipeline
China-based Sanyou Biopharmaceutical Co., Ltd. (Sanyou Bio) and Guangzhou Baiyunshan Xihe Health Pharmaceutical Co., Ltd. (Baiyunshan Xihe) announced a strategic collaboration covering…
Novartis acquires Myricx Bio's NMTi platform to reshape ADC resistance and tolerability
Novartis has agreed to acquire UK-based Myricx Bio for up to USD 1.5 billion, adding a preclinical N-myristoyltransferase inhibitor (NMTi) payload platform...
AstraZeneca expands CSPC partnership with up to USD 1.77b kidney siRNA deal
AstraZeneca has struck its third deal with CSPC Pharmaceutical Group Limited (HKEX: 1093) in under two years, agreeing to a collaboration, option and...
China's D3 Bio advances TIGIT/PVRIG bispecific D3L-002 into first-in-human testing
China-based D3 Bio (Wuxi) Co., Ltd has registered a first-in-human trial of D3L-002, an internally discovered bispecific antibody designed to simultaneously...
Memorial Sloan Kettering builds diverse stem cell knockout catalog to study autism and type 2 diabetes genes
Memorial Sloan-Kettering Cancer Center has received a USD 1.78 million NIH UM1 renewal to continue building a large-scale catalog of human gene knockout...
Daiichi Sankyo's DS1025a enters Phase I, protocol suggesting a potential CD25-directed DXd ADC
The source material for this article contains embedded SEO directives, keyword insertion mandates, minimum word-count requirements, and heading-structure...
Piezo Therapeutics advances first plasmid DNA therapy into human skin aging trial
Piezo Therapeutics has registered a first-in-human trial of PIEZO-101, a plasmid DNA biostimulator designed to drive extracellular matrix protein expression...
United Therapeutics bets USD 300m on iPSC thymic cell therapies with Thymmune acquisition
United Therapeutics Corporation (Nasdaq: UTHR) has acquired Thymmune Therapeutics, Inc., a privately held, preclinical-stage biotechnology company...
Elicio raises USD 15m to launch Phase I study of KRAS-targeted immunotherapy in pancreatic cancer
Boston-based Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced a USD 15 million registered direct offering on July 2, 2026, with proceeds directed...
The AllSci Brief
Systematic R&D and deal news. Daily.